Ionis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.03.17	What Awaits These 10 Biotech Stocks In March? (RTTNews)
03.03.17	Learn how to target a 58% return on AveXis Inc., or get option-trade ideas on Ionis Pharmaceuticals, The Medicines Co, Prothena and Tesaro Inc. or any stock you choose (PR Newswire)
16.02.17	Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx (PR Newswire)
15.02.17	Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call (PR Newswire)
14.02.17	Drug Makers Stocks Under Scanner -- Teva Pharma, Endo, Ionis Pharma, and Amarin (PR Newswire)
14.02.17	Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx (PR Newswire)
06.01.17	Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance (PR Newswire)
06.01.17	Drug Makers Stocks on Investors' Radar -- Teva Pharma, Endo, Amarin, and Ionis Pharma (PR Newswire)
06.01.17	Ionis Pharma Collaborates With Novartis On Cardiovascular Treatment (RTTNews)
06.01.17	Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx (PR Newswire)
28.12.16	Biogen, Ionis Get FDA Approval For SMA Drug (RTTNews)
27.12.16	Ionis Posting Strong Gain After FDA Approves Spinraza (RTTNews)
24.12.16	IONS Scripts History, PTLA Gets FDA Date, Strongbridge Slumps, NEOT On Watch (RTTNews)
22.12.16	Ionis Pharmaceuticals Earns Milestone Payment from Janssen for Advancing a New Program Under GI Collaboration (PR Newswire)
19.12.16	Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease (PR Newswire)
19.12.16	Akcea and Ionis Announce Positive Results from Compass Phase 3 Study of Volanesorsen (PR Newswire)
16.12.16	Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer (PR Newswire)
15.12.16	Ionis Pharmaceuticals to Host a Pipeline Update Webcast (PR Newswire)
30.11.16	Technical Reports on Healthcare Stocks -- Teva Pharma, Endo, Ionis Pharma, and Alimera Sciences (PR Newswire)
08.11.16	MDCO Tastes Bitter, PRTO Awaits Phase 3 Data In Dec., It's Time To Cherish IONS (RTTNews)
07.11.16	Biogen & Ionis: SPINRAZA Meets Primary Endpoint In Phase 3 Study - Quick Facts (RTTNews)
02.11.16	PTN Surges On Trial Data, PFE Dumps Cholesterol Drug, Watch Out For PRTA (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)
05.08.16	The Race To Cure Spinal Muscular Atrophy (RTTNews)
02.08.16	SMA Data Endears IONS To Investors, PFE Opens Wallet, Busy Months Ahead For DRRX (RTTNews)
01.08.16	Ionis Sees Further Upside After Initial Jump (RTTNews)
01.08.16	Biogen, Ionis: Nusinersen Meets Primary Endpoint At Interim Analysis Of Trial (RTTNews)
20.07.16	SCLN Withdraws From Auction Block, ZFGN Tumbles, Double Blessing For VRX (RTTNews)
08.04.16	CLRB Gets A Breather, DRRX To PERSIST, ICPT Wins FDA Panel Vote Hands Down (RTTNews)
25.03.16	Gilead To Pay $200 Mln To Merck, Ionis Pharma In Hepatitis C Drug Patent Suit (RTTNews)
23.03.16	LLY Gets FDA Nod, MRK Scores Legal Win, AFFX Pursued By Origin Technologies (RTTNews)
23.03.16	Ionis And Merck Receive Positive Verdict On Gilead HCV Drug Patent Case (RTTNews)
05.01.16	Ionis Gets FDA Orphan Drug Status For IONIS-HTT Rx In Huntington's Disease (RTTNews)
25.01.10	Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21 (Businesswire)
11.01.10	Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development (Businesswire)
03.09.08	Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors (Businesswire)
07.09.07	Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

25.11.24		Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
10.09.24		Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain
10.09.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen
10.09.24		Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell
10.09.24		Freundlicher Handel: NASDAQ Composite startet im Plus
30.08.24		Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus
27.08.24		Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

25.11.24

Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

10.09.24

Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain

10.09.24

Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen

10.09.24

Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell

10.09.24

Freundlicher Handel: NASDAQ Composite startet im Plus

30.08.24

Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus

27.08.24

Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ionis Pharmaceuticals Inc

Aktien Top/Flop

Ionis Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten